Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sonnet BioTherapeutics Q1 EPS $(0.31) May Not Be Comparable To $(0.90) Estimate, Sales $18.63K Beat $18.00K Estimate

Author: Benzinga Newsdesk | February 14, 2024 09:00am
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.90) by 65.56 percent. This is a 98.24 percent increase over losses of $(17.60) per share from the same period last year. The company reported quarterly sales of $18.63 thousand which beat the analyst consensus estimate of $18.00 thousand by 3.48 percent. This is a 50.00 percent decrease over sales of $37.26 thousand the same period last year.

Posted In: SONN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist